Xenetic Biosciences, Inc. (XBIO) Stock Price & Analysis

Xenetic Biosciences, Inc. (XBIO) rose 0.86% to USD 4.67 as of September 8, 2026 at 06:58 UTC, according to Nexqual real-time market data.

XBIO last closed at USD 4.67; the session ranged USD 4.41–4.9 on volume of 79,165 shares. Market capitalization is —, with a 52-week range of USD 1.9–13.93 (NCM). Source: Nexqual, September 8, 2026 at 06:58 UTC.

Key Statistics (as of September 8, 2026 at 06:58 UTC)

Technical Analysis (XBIO)

Nexqual's technical model rates XBIO "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 06:58 UTC.

From Xenetic Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• We have not been actively pursuing development efforts for XCART or PolyXen or any of our other technologies.     Research, Outside Services and Collaborations   Through partner efforts, we are developing our pipeline of next-generation bio-therapeutics and novel oncology drugs based on our DNase proprietary technology.
• We also rely on trade secrets and know-how relating to our proprietary technology and product candidates, continuing innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of oncology.
• Regulation   Drug Development Process   In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act ("FDCA"), and in the case of biologics, also under the Public Health Service Act and the FDCA, and their implementing regulations.
• The first developer to receive FDA marketing approval for an orphan drug is entitled to a seven-year exclusive marketing period in the U.S. for that product.

Partnerships

• All other terms of the Scripps Agreement remain unchanged.   Effective May 1, 2025, we entered into a Third Amendment to the Scripps Agreement with Scripps Research (the "Third Amendment"), pursuant to which we expanded the services to be performed under the Scripps Agreement and provided Scripps Research additional funding in an aggregate amount of up to approximately $0.4 million to fund continuing research.
• The conduct of several CAR T in vivo models has been a primary focus of our Scripps collaboration.   We have partnered with biotechnology and pharmaceutical companies to develop our proprietary drug delivery platform, PolyXen, and receive royalty payments under an exclusive license arrangement in the field of blood coagulation disorders.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:58 UTC. This page is informational and not investment advice.